Japan remains the world’s second-largest individual pharmaceutical market, characterized by a sophisticated regulatory environment and a rapidly aging population. For global pharmaceutical companies, entering this market is a high-reward venture that carries a significant responsibility: maintaining rigorous post-marketing safety standards. As we move into 2026, the Japanese regulatory landscape is evolving. With the PMDA (Pharmaceuticals and Medical…